Improved Revenues Required Before Guangdong Hybribio Biotech Co.,Ltd. (SZSE:300639) Stock's 45% Jump Looks Justified

Simply Wall StOct 8 19:58 ET

Guangdong Hybribio Biotech (300639.SZ): The company and its subsidiaries have been granted a patent for invention.

Gelonghui September 30th | Guangdong Hybribio Biotech (300639.SZ) announced that the company and its subsidiaries obtained an invention patent in September 2024. The invention patent is for a reagent kit and its application for extracting genomic DNA from dried blood spots using a magnetic bead method. This invention relates to the technical field of nucleic acid extraction, providing a reagent kit and its application for extracting genomic DNA from dried blood spots using a magnetic bead method. The kit consists of a nucleic acid releasing agent, lysis solution, magnetic beads, wash solution I, wash solution II, and elution solution. This invention adds NaOH and guanidine hydrochloride to the nucleic acid releasing agent to rapidly lyse cells, release nucleic acids, and at the same time

Gelonghui FinanceSep 30 04:06 ET

Strong Week for Guangdong Hybribio BiotechLtd (SZSE:300639) Shareholders Doesn't Alleviate Pain of Three-year Loss

Simply Wall StSep 30 00:23 ET

Hybribio Biotech Unit Gets Nod to Trial Chloroquine Phosphate Gel

MT NewswiresSep 23 04:23 ET

Guangdong Hybribio Biotech (300639.SZ): The wholly-owned subsidiary, Chloroquine Phosphate Gel, has obtained the Notice of Approval for Clinical Trials of Medicines.

Gelonghui September 20th | Guangdong Hybribio Biotech (300639.SZ) announced that recently, its wholly-owned subsidiary Guangzhou Guangdong Hybribio Technology Co., Ltd. has received the drug clinical trial approval notice for "Chloroquine Phosphate Gel" issued by the National Medical Products Administration, allowing the product to conduct clinical trials for high-risk HPV virus infections.

Gelonghui FinanceSep 20 08:10 ET

Guangdong Hybribio Biotech Unit Gets China Nod for HPV Diagnostic Kit

MT NewswiresSep 11 02:03 ET